Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.

PAPERS | | |

Source: Headache 2023 Jan 12; . doi: 10.1111/head.14434Authors: Starling AJ, Cowan RP, Buse DC, Diener H-C, Marmura MJ, Hirman J, Brevig T, Cady R

To evaluate the effect of eptinezumab on patient-reported outcomes in patients with chronic migraine (CM) and medication-overuse headache (MOH).

Pubmed ID: http://www.ncbi.nlm.nih.gov/pubmed/36633219?dopt=Abstract

Paper chosen by Rebecca Seal

Leave a Comment

You must be logged in to post a comment.

Recent Papers

The analgesic efficacy of opioids in different application modalities for the treatment of breakthrough cancer pain-a systematic review with network meta-analysis

October 16, 2026 | Basic Research,  Clinical Research

Emotional imagery alters symptom perception but not postural or respiratory behavior in individuals with chronic non-specific low back pain

October 16, 2026 | Clinical Research

Headache disorders among Indigenous communities: A scoping review undertaken with knowledge keeper guidance

October 16, 2026 | Clinical Research

Plasma amylin levels in migraine and after erenumab treatment: A REFORM study

October 16, 2026 | Clinical Research

The MIND study: Design, feasibility, and baseline characteristics of a smartphone-based migraine cohort

October 16, 2026 | Clinical Research